Comparison of tablet and disk diffusion methods for fluconazole and voriconazole in vitro activity testing against clinical yeast isolates.
We have compared a commercially available tablet diffusion method for the in vitro antifungal susceptibility testing of fluconazole (FCZ) and voriconazole (VCZ) with the disk diffusion method M44 (CLSI) with 282 clinical yeast isolates. The superior stability of antifungal agents in tablets can explain the differences for each category of susceptibility by both methods.Neo-Sensitabs tablets antifungal susceptibility testing showed an excellent correlation (0.98 for FCZ and 0.98 for VCZ at 24h and 0.96 for FCZ and 0.94 for VCZ at 48 h ), a reduced percentage of disagreements (4.6% and 8.2% for FCZ at 24h and 48 h respectively; 1.1% and 2.1% for VCZ at 24h and 48 h respectively) and the absence of statistically significant difference in comparison with the reference protocol for performing antifungal susceptibility testing with the agar diffusion method.
Rementeria
A
A
Departamento de Immunología, Microbiología y Parasitología, Universidad del País Vasco, Bilbao, Spain.
Sanchez-Vargas
L O
LO
Villar
M
M
Casals
J B
JB
Carrillo-Munoz
A J
AJ
Rodriguez Andres
C
C
Eraso
E
E
Quindos
G
G
D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects; D002478:Cells, Cultured; D025141:Drug Resistance, Fungal / Q000187:drug effects*; D015725:Fluconazole / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D016014:Linear Models; D008826:Microbial Sensitivity Tests / Q000379:methods*; D011743:Pyrimidines / Q000494:pharmacology*; D015203:Reproducibility of Results; D012440:Saccharomyces / Q000187:drug effects; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D015725:Fluconazole; D065819:Voriconazole